Literature DB >> 29434893

Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES-1 gene expression and H3K27me3 demethylation.

Zhenshu Xu1, Donglian Xiong1, Jushun Zhang1, Jingyan Zhang1, Xiuli Chen1, Zhizhe Chen1, Rong Zhan1.   

Abstract

The majority of patients with chronic lymphocytic leukemia (CLL) are not cured by traditional chemotherapy. One possible explanation for this is that the microenvironment protects CLL cells from both spontaneous- and cytotoxic-mediated apoptosis. The present study was designed to investigate the mechanisms accounting for these effects, since this information is crucial to understanding CLL physiopathology and identifying potential treatment targets. The CLL cell line L1210 and primary CLL cells were cultured under different conditions: With serum, cyclophosphamide (CTX), or with monolayers and conditioned medium (CM) from the stromal cell line HESS-5. Apoptosis, Hes family BHLH transcription factor 1 (HES-1) gene and protein expression, and histone H3K27me3 DNA demethylation were determined. Co-culture of L1210 cells with HESS-5 cells significantly inhibited serum deprivation- and CTX-induced apoptosis of leukemia cells, and resulted in a significant increase in short-term proliferation. Soluble factors in the CM from HESS-5 cells had a negligible effect. The HESS-5 cell-mediated inhibition of apoptosis of CLL cells was associated with increased HES-1 expression and hypomethylation of the H3K27me3 gene in the leukemia cells. These results indicate that stromal cells enhance the survival of CLL cells by regulating the HES-1 gene and protein expression, as well as H3K27me3 DNA demethylation, and suggest that specific interactions between stromal and leukemia cells may enhance the resistance of leukemia cells to chemotherapy.

Entities:  

Keywords:  CLL; H3K27me3; HES-1; demethylation; stromal cells

Year:  2017        PMID: 29434893      PMCID: PMC5774425          DOI: 10.3892/ol.2017.7450

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

1.  Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.

Authors:  Jiro Kikuchi; Daisuke Koyama; Taeko Wada; Tohru Izumi; Peter O Hofgaard; Bjarne Bogen; Yusuke Furukawa
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

2.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

3.  Murine stromal cell line HESS-5 maintains reconstituting ability of Ex vivo-generated hematopoietic stem cells from human bone marrow and cytokine-mobilized peripheral blood.

Authors:  Y Shimakura; H Kawada; K Ando; T Sato; Y Nakamura; T Tsuji; S Kato; T Hotta
Journal:  Stem Cells       Date:  2000       Impact factor: 6.277

4.  Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.

Authors:  Sonia Fabris; Valentina Bollati; Luca Agnelli; Fortunato Morabito; Valeria Motta; Giovanna Cutrona; Serena Matis; Anna Grazia Recchia; Vincenzo Gigliotti; Massimo Gentile; Giorgio Lambertenghi Deliliers; Pier Alberto Bertazzi; Manlio Ferrarini; Antonino Neri; Andrea Baccarelli
Journal:  Epigenetics       Date:  2011-02-01       Impact factor: 4.528

5.  New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling.

Authors:  José I Martín-Subero; Markus Kreuz; Marina Bibikova; Stefan Bentink; Ole Ammerpohl; Eliza Wickham-Garcia; Maciej Rosolowski; Julia Richter; Lidia Lopez-Serra; Esteban Ballestar; Hilmar Berger; Xabier Agirre; Heinz-Wolfram Bernd; Vincenzo Calvanese; Sergio B Cogliatti; Hans G Drexler; Jian-Bing Fan; Mario F Fraga; Martin L Hansmann; Michael Hummel; Wolfram Klapper; Bernhard Korn; Ralf Küppers; Roderick A F Macleod; Peter Möller; German Ott; Christiane Pott; Felipe Prosper; Andreas Rosenwald; Carsten Schwaenen; Dirk Schübeler; Marc Seifert; Benjamin Stürzenhofecker; Michael Weber; Swen Wessendorf; Markus Loeffler; Lorenz Trümper; Harald Stein; Rainer Spang; Manel Esteller; David Barker; Dirk Hasenclever; Reiner Siebert
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

6.  Mutual education between hematopoietic cells and bone marrow stromal cells through direct cell-to-cell contact: factors that determine the growth of bone marrow stroma-dependent leukemic (HB-1) cells.

Authors:  H Jiang; K Sugimoto; H Sawada; E Takashita; M Tohma; H Gonda; K J Mori
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

7.  Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.

Authors:  Shilu Amin; Meagan Walsh; Caroline Wilson; Anton E Parker; David Oscier; Elaine Willmore; Derek Mann; Jelena Mann
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

Review 8.  New antibody approaches to lymphoma therapy.

Authors:  Tejas Suresh; Lisa X Lee; Jitesh Joshi; Stefan K Barta
Journal:  J Hematol Oncol       Date:  2014-09-09       Impact factor: 17.388

9.  Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.

Authors:  Quanyi Lu; Xianghua Lin; Jean Feng; Xiangmin Zhao; Ruth Gallagher; Marietta Y Lee; Jen-Wei Chiao; Delong Liu
Journal:  J Hematol Oncol       Date:  2008-06-09       Impact factor: 17.388

Review 10.  Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.

Authors:  Jingjing Wu; Jiaping Fu; Mingzhi Zhang; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

View more
  2 in total

1.  Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.

Authors:  Ti'ara L Griffen; Fieke W Hoff; Yihua Qiu; James W Lillard; Alessandra Ferrajoli; Philip Thompson; Endurance Toro; Kevin Ruiz; Jan Burger; William Wierda; Steven M Kornblau
Journal:  Blood Cancer J       Date:  2022-03-17       Impact factor: 11.037

Review 2.  Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.

Authors:  Erwan Dumontet; Stéphane J C Mancini; Karin Tarte
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.